Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
| Autor: | Samia Abed Maillard, Lukas Flatz, Daniel E. Speiser, Reinhard Rüesch, Fabienne Keller, Stefan Diem, Simone M. Goldinger, Ursula Urner-Bloch, Reinhard Dummer, Marco Siano |
|---|---|
| Přispěvatelé: | University of Zurich, Flatz, Lukas |
| Rok vydání: | 2016 |
| Předmět: |
Oncology
Male Cancer Research medicine.medical_specialty Skin Neoplasms medicine.medical_treatment Immunology Programmed Cell Death 1 Receptor 610 Medicine & health Ipilimumab Autoimmunity Pembrolizumab Antibodies Monoclonal Humanized Uveitis 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Immunology and Allergy Humans 1306 Cancer Research CTLA-4 Antigen Colitis Melanoma Aged Pharmacology 2403 Immunology Surrogate endpoint business.industry 10177 Dermatology Clinic Immunotherapy Middle Aged medicine.disease 3. Good health 3004 Pharmacology Treatment Outcome 030220 oncology & carcinogenesis Monoclonal 2723 Immunology and Allergy 030221 ophthalmology & optometry Neoplasms Unknown Primary business medicine.drug |
| Zdroj: | Journal of Immunotherapy |
| ISSN: | 1537-4513 |
| Popis: | Immunotherapy leads to significantly prolonged survival of patients with metastatic melanoma. Autoimmune side effects including colitis, dermatitis, and endocrine abnormalities are common in patients treated with ipilimumab [anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4)]. Antibodies such as pembrolizumab that interfere with the PD-1 (programmed cell death 1)/PD-L1 pathway show greater efficacy and less toxicity than ipilimumab. Here we report 2 cases of pembrolizumab-induced uveitis associated with complete or partial tumor response. We suggest that uveitis may serve as a surrogate marker for a tumor response to therapy with pembrolizumab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|